Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients

So Yeon Oh; Sang Won Shin; Su Jin Koh; Sang Byung Bae; Hyun Chang; Jung Han Kim; Hyo Jung Kim; Young Seon Hong; Keon Uk Park; Jeanno Park; Kyung Hee Lee; Na Ri Lee; Jung Lim Lee; Joung Soon Jang; Dae Sik Hong; Seung Sei Lee; Sun Kyung Baek; Dae Ro Choi; Jooseop Chung; Sang Cheul Oh; Hye Sook Han; Hwan Jung Yun; Sun Jin Sym; So Young Yoon; In Sil Choi; Byoung Yong Shim; Seok Yun Kang; Sung Rok Kim; Hyun Joo Kim

doi:10.1007/s00520-017-3806-5

Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients

So Yeon Oh, Sang Won Shin, Su Jin Koh, Sang Byung Bae, Hyun Chang, Jung Han Kim, Hyo Jung Kim, Young Seon Hong, Keon Uk Park, Jeanno Park, Kyung Hee Lee, Na Ri Lee, Jung Lim Lee, Joung Soon Jang, Dae Sik Hong, Seung Sei Lee, Sun Kyung Baek, Dae Ro Choi, Jooseop Chung, Sang Cheul OhHye Sook Han, Hwan Jung Yun, Sun Jin Sym, So Young Yoon, In Sil Choi, Byoung Yong Shim, Seok Yun Kang, Sung Rok Kim, Hyun Joo Kim

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Purpose: Neuropathic cancer pain (NCP) is a common and potentially debilitating symptom in cancer patients. We investigated the prevalence of NCP, as well as its management and association with QOL. Methods: Cancer patients with pain ≥1 on the visual analogue scale (VAS) were surveyed with the Douleur Neuropathique (DN4) questionnaire, the Brief Pain Inventory-Short Form (BPI-SF), and the EuroQOL five dimensions (EQ-5D) questionnaire. The associations between NCP and pain severity or NCP and QOL, while controlling for variables relevant to QOL, were then analyzed. Results: A total of 2003 patients were enrolled in this survey; the prevalence of NCP was 36.0% (n = 722, 95% CI, 32.5–39.5). We found that NCP in cancer patients was closely correlated to a higher pain severity (BPI-SF; 4.96 ± 1.94 versus 4.24 ± 2.02, p < 0.001), and in patients with NCP, pain more severely interfered with daily living, as compared to those without NCP (BPI-SF; 4.86 ± 2.71 versus 4.41 ± 2.87, p < 0.001). Patients with NCP also had worse QOL than those without NCP, as measured by EQ-5D index score (0.47 ± 0.30 vs. 0.51 ± 0.30, p = 0.005), and this was confirmed using multivariate analysis (p < 0.001), even after controlling for other variables such as age, sex, disease stage, cancer duration, radiotherapy, chemotherapy, and comorbidities. Importantly, adjuvant analgesics were used in less than half of patients with NCP (n = 358, 46.4%). Conclusions: We found that NCP in cancer patients was significantly associated with a worsened QOL, and current management is inadequate. Therefore, future research aimed at developing improved strategies for management of NCP is required.

Original language	English
Pages (from-to)	3759-3767
Number of pages	9
Journal	Supportive Care in Cancer
Volume	25
Issue number	12
DOIs	https://doi.org/10.1007/s00520-017-3806-5
Publication status	Published - 2017 Dec 1

Keywords

Neoplasm
Neuropathic pain
Pain management
Quality of life

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00520-017-3806-5

Cite this

Oh, S. Y., Shin, S. W., Koh, S. J., Bae, S. B., Chang, H., Kim, J. H., Kim, H. J., Hong, Y. S., Park, K. U., Park, J., Lee, K. H., Lee, N. R., Lee, J. L., Jang, J. S., Hong, D. S., Lee, S. S., Baek, S. K., Choi, D. R., Chung, J., ... Kim, H. J. (2017). Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. Supportive Care in Cancer, 25(12), 3759-3767. https://doi.org/10.1007/s00520-017-3806-5

Oh, SY, Shin, SW, Koh, SJ, Bae, SB, Chang, H, Kim, JH, Kim, HJ, Hong, YS, Park, KU, Park, J, Lee, KH, Lee, NR, Lee, JL, Jang, JS, Hong, DS, Lee, SS, Baek, SK, Choi, DR, Chung, J, Oh, SC, Han, HS, Yun, HJ, Sym, SJ, Yoon, SY, Choi, IS, Shim, BY, Kang, SY, Kim, SR & Kim, HJ 2017, 'Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients', Supportive Care in Cancer, vol. 25, no. 12, pp. 3759-3767. https://doi.org/10.1007/s00520-017-3806-5

@article{c884bbbb5d214786a4c7ec084b464114,

title = "Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients",

abstract = "Purpose: Neuropathic cancer pain (NCP) is a common and potentially debilitating symptom in cancer patients. We investigated the prevalence of NCP, as well as its management and association with QOL. Methods: Cancer patients with pain ≥1 on the visual analogue scale (VAS) were surveyed with the Douleur Neuropathique (DN4) questionnaire, the Brief Pain Inventory-Short Form (BPI-SF), and the EuroQOL five dimensions (EQ-5D) questionnaire. The associations between NCP and pain severity or NCP and QOL, while controlling for variables relevant to QOL, were then analyzed. Results: A total of 2003 patients were enrolled in this survey; the prevalence of NCP was 36.0% (n = 722, 95% CI, 32.5–39.5). We found that NCP in cancer patients was closely correlated to a higher pain severity (BPI-SF; 4.96 ± 1.94 versus 4.24 ± 2.02, p < 0.001), and in patients with NCP, pain more severely interfered with daily living, as compared to those without NCP (BPI-SF; 4.86 ± 2.71 versus 4.41 ± 2.87, p < 0.001). Patients with NCP also had worse QOL than those without NCP, as measured by EQ-5D index score (0.47 ± 0.30 vs. 0.51 ± 0.30, p = 0.005), and this was confirmed using multivariate analysis (p < 0.001), even after controlling for other variables such as age, sex, disease stage, cancer duration, radiotherapy, chemotherapy, and comorbidities. Importantly, adjuvant analgesics were used in less than half of patients with NCP (n = 358, 46.4%). Conclusions: We found that NCP in cancer patients was significantly associated with a worsened QOL, and current management is inadequate. Therefore, future research aimed at developing improved strategies for management of NCP is required.",

keywords = "Neoplasm, Neuropathic pain, Pain management, Quality of life",

author = "Oh, {So Yeon} and Shin, {Sang Won} and Koh, {Su Jin} and Bae, {Sang Byung} and Hyun Chang and Kim, {Jung Han} and Kim, {Hyo Jung} and Hong, {Young Seon} and Park, {Keon Uk} and Jeanno Park and Lee, {Kyung Hee} and Lee, {Na Ri} and Lee, {Jung Lim} and Jang, {Joung Soon} and Hong, {Dae Sik} and Lee, {Seung Sei} and Baek, {Sun Kyung} and Choi, {Dae Ro} and Jooseop Chung and Oh, {Sang Cheul} and Han, {Hye Sook} and Yun, {Hwan Jung} and Sym, {Sun Jin} and Yoon, {So Young} and Choi, {In Sil} and Shim, {Byoung Yong} and Kang, {Seok Yun} and Kim, {Sung Rok} and Kim, {Hyun Joo}",

note = "Funding Information: This research was sponsored by Pfizer. Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s00520-017-3806-5",

language = "English",

volume = "25",

pages = "3759--3767",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "12",

}

TY - JOUR

T1 - Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients

AU - Oh, So Yeon

AU - Shin, Sang Won

AU - Koh, Su Jin

AU - Bae, Sang Byung

AU - Chang, Hyun

AU - Kim, Jung Han

AU - Kim, Hyo Jung

AU - Hong, Young Seon

AU - Park, Keon Uk

AU - Park, Jeanno

AU - Lee, Kyung Hee

AU - Lee, Na Ri

AU - Lee, Jung Lim

AU - Jang, Joung Soon

AU - Hong, Dae Sik

AU - Lee, Seung Sei

AU - Baek, Sun Kyung

AU - Choi, Dae Ro

AU - Chung, Jooseop

AU - Oh, Sang Cheul

AU - Han, Hye Sook

AU - Yun, Hwan Jung

AU - Sym, Sun Jin

AU - Yoon, So Young

AU - Choi, In Sil

AU - Shim, Byoung Yong

AU - Kang, Seok Yun

AU - Kim, Sung Rok

AU - Kim, Hyun Joo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose: Neuropathic cancer pain (NCP) is a common and potentially debilitating symptom in cancer patients. We investigated the prevalence of NCP, as well as its management and association with QOL. Methods: Cancer patients with pain ≥1 on the visual analogue scale (VAS) were surveyed with the Douleur Neuropathique (DN4) questionnaire, the Brief Pain Inventory-Short Form (BPI-SF), and the EuroQOL five dimensions (EQ-5D) questionnaire. The associations between NCP and pain severity or NCP and QOL, while controlling for variables relevant to QOL, were then analyzed. Results: A total of 2003 patients were enrolled in this survey; the prevalence of NCP was 36.0% (n = 722, 95% CI, 32.5–39.5). We found that NCP in cancer patients was closely correlated to a higher pain severity (BPI-SF; 4.96 ± 1.94 versus 4.24 ± 2.02, p < 0.001), and in patients with NCP, pain more severely interfered with daily living, as compared to those without NCP (BPI-SF; 4.86 ± 2.71 versus 4.41 ± 2.87, p < 0.001). Patients with NCP also had worse QOL than those without NCP, as measured by EQ-5D index score (0.47 ± 0.30 vs. 0.51 ± 0.30, p = 0.005), and this was confirmed using multivariate analysis (p < 0.001), even after controlling for other variables such as age, sex, disease stage, cancer duration, radiotherapy, chemotherapy, and comorbidities. Importantly, adjuvant analgesics were used in less than half of patients with NCP (n = 358, 46.4%). Conclusions: We found that NCP in cancer patients was significantly associated with a worsened QOL, and current management is inadequate. Therefore, future research aimed at developing improved strategies for management of NCP is required.

AB - Purpose: Neuropathic cancer pain (NCP) is a common and potentially debilitating symptom in cancer patients. We investigated the prevalence of NCP, as well as its management and association with QOL. Methods: Cancer patients with pain ≥1 on the visual analogue scale (VAS) were surveyed with the Douleur Neuropathique (DN4) questionnaire, the Brief Pain Inventory-Short Form (BPI-SF), and the EuroQOL five dimensions (EQ-5D) questionnaire. The associations between NCP and pain severity or NCP and QOL, while controlling for variables relevant to QOL, were then analyzed. Results: A total of 2003 patients were enrolled in this survey; the prevalence of NCP was 36.0% (n = 722, 95% CI, 32.5–39.5). We found that NCP in cancer patients was closely correlated to a higher pain severity (BPI-SF; 4.96 ± 1.94 versus 4.24 ± 2.02, p < 0.001), and in patients with NCP, pain more severely interfered with daily living, as compared to those without NCP (BPI-SF; 4.86 ± 2.71 versus 4.41 ± 2.87, p < 0.001). Patients with NCP also had worse QOL than those without NCP, as measured by EQ-5D index score (0.47 ± 0.30 vs. 0.51 ± 0.30, p = 0.005), and this was confirmed using multivariate analysis (p < 0.001), even after controlling for other variables such as age, sex, disease stage, cancer duration, radiotherapy, chemotherapy, and comorbidities. Importantly, adjuvant analgesics were used in less than half of patients with NCP (n = 358, 46.4%). Conclusions: We found that NCP in cancer patients was significantly associated with a worsened QOL, and current management is inadequate. Therefore, future research aimed at developing improved strategies for management of NCP is required.

KW - Neoplasm

KW - Neuropathic pain

KW - Pain management

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85021993408&partnerID=8YFLogxK

U2 - 10.1007/s00520-017-3806-5

DO - 10.1007/s00520-017-3806-5

M3 - Article

C2 - 28689250

AN - SCOPUS:85021993408

SN - 0941-4355

VL - 25

SP - 3759

EP - 3767

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 12

ER -

Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this